The approval is expected to further accelerate its growth in the European market and provide surgeons with more options for treating cervical degenerative disc disease.
“We are extremely pleased by the continuing regulatory recognition for our innovative products in the cervical spine market,” said Margaret Wong, director of regulatory affairs at Providence. “This CE Mark also gives us a clear regulatory path for new implants and instruments within the DTRAX family in the European Union.”
More articles on devices:
NuVasive’s 2014 revenue up 11.3% — 10 key notes
Medtronic Spine to honor Dr. Kenneth Robinson
ChoiceSpine brings former Alphatec, TranS1 execs onboard — 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
